Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10899062 | 0.83 | SHBG (0.41) | SHBGALDH1A1NPSR1 | |
| SCHEMBL3751601 | 0.75 | SHBG (0.38) | SHBG | |
| SCHEMBL9719516 | 0.71 | SHBG (0.40) | SHBG | |
| SCHEMBL29251117 | 0.70 | SHBG (0.33) | SHBG | |
| SCHEMBL12918643 | 0.69 | ALDH1A1 (0.32) | SHBGALDH1A1NPSR1 | |
| SCHEMBL8010811 | 0.69 | SHBG (0.35) | SHBG | |
| SCHEMBL7285053 | 0.69 | EPHX1 (0.36) | SHBGALDH1A1 | |
| SCHEMBL7497508 | 0.69 | SHBG (0.36) | SHBG | |
| SCHEMBL6437481 | 0.68 | SHBG (0.46) | SHBGALDH1A1NPSR1 | |
| SCHEMBL16992889 | 0.67 | SHBG (0.44) | SHBGALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605947-A1 | USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA, AND DISORDERS ASSOCIATED WITH AN INCREASED LEVEL OF CYTOTOXIC REACTIVE OXYGEN SPECIES | Vasopharm Biotech GmbH (DE) | 2005-12-21 | — | — | EP | claimed |
| WO-2005037286-A1 | USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE AND SECONDARY ISCHEMIA | VASOPHARM BIOTECH GMBH (DE) | 2005-04-28 | — | — | WO | claimed |
| WO-2004084906-A1 | USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA, AND DISORDERS ASSOCIATED WITH AN INCREASED LEVEL OF CYTOTOXIC REACTIVE OXYGEN SPECIES | VASOPHARM BIOTECH GMBH (DE) | 2004-10-07 | — | — | WO | claimed |
| US-20130184281-A1 | USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA, AND DISORDERS ASSOCIATED WITH AN INCREASED LEVEL OF CYTOTOXIC REACTIVE OXYGEN SPECIES | VASOPHARM BIOTECH GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-1605947-B1 | USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE | VASOPHARM BIOTECH GMBH (DE) | 2006-08-02 | — | — | EP | disclosed |
| EP-1605947-A1 | USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA, AND DISORDERS ASSOCIATED WITH AN INCREASED LEVEL OF CYTOTOXIC REACTIVE OXYGEN SPECIES | Vasopharm Biotech GmbH (DE) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005037286-A1 | USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE AND SECONDARY ISCHEMIA | VASOPHARM BIOTECH GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
| WO-2004084906-A1 | USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA, AND DISORDERS ASSOCIATED WITH AN INCREASED LEVEL OF CYTOTOXIC REACTIVE OXYGEN SPECIES | VASOPHARM BIOTECH GMBH (DE) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184281-A1 | USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA, AND DISORDERS ASSOCIATED WITH AN INCREASED LEVEL OF CYTOTOXIC REACTIVE OXYGEN SPECIES | IMPDH1, NME4, IDH2 | SHBG 4298/4885ALDH1A1 2332/4885NPSR1 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.